Few events are harder to deal with than sudden death in young people. Each year in the United States, about one in 200 000 high school or college athletes will die suddenly, the vast majority without any prior symptoms,1 and these devastating events are often the first clinical manifestation of an underlying cardiovascular disorder. Indeed, about 90% of sudden deaths, defined as death occurring within one hour of the onset of symptoms, are found to be caused by cardiac structural pathology in autopsy-based series. The remaining 10% relate to other cardiac electrical disorders, such as long-QT syndrome and Wolf–Parkinson–White syndrome, or commotio cordis (the result of sudden sharp chest blows), as well as complications of asthma, substance misuse, and sudden infant death syndrome (SIDS).2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes — clinical, demographic and pathological profiles. JAMA 1996; 276: 199-204.
- 2. Maron BJ. Heart disease and other causes of sudden death in young athletes. Curr Probl Cardiol 1998; 23: 477-529.
- 3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
- 4. Semsarian C, Richmond DR. Sudden cardiac death in familial hypertrophic cardiomyopathy: an Australian experience. Aust N Z J Med 1999; 29: 368-370.
- 5. Seidman CE, Seidman JG. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104: 557-567.
- 6. Semsarian C, Seidman CE. Molecular medicine in the 21st century. Intern Med J 2001; 31: 53-59.
- 7. Watkins H, Rosenzweig A, Hwang D, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1108-1114.
- 8. Macilwain C. World leaders heap praise on human genome landmark. Nature 2000; 405: 983-984.
- 9. Maron BJ, Shen W, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-373.
- 10. Teare D. Asymmetrical hypertrophy of the heart in the young adults. Br Heart J 1958; 20: 1-8.
Christopher Semsarian is supported by a National Heart Foundation of Australia fellowship.
None declared.